Abstract

Cambrex is expanding its large-scale active pharmaceutical ingredient operation in Karlskoga, Sweden, introducing continuous-flow production of high-purity drug intermediates. The expansion will also add multipurpose batch reactors ranging from 4 to 12 m3, a 9-m3 hydrogenation reactor, and an upgraded control room. Work on the project is set to be completed later this year.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call